Collegium Pharmaceutical Inc. (NASDAQ:COLL)’s share price shot up 4.6% during mid-day trading on Thursday . The company traded as high as $8.84 and last traded at $8.71, with a volume of 118,884 shares traded. The stock had previously closed at $8.33.

A number of brokerages recently issued reports on COLL. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price (up from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $26.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $28.25.

The firm’s 50-day moving average is $11.47 and its 200 day moving average is $15.39. The company’s market cap is $207.75 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. On average, equities analysts anticipate that Collegium Pharmaceutical Inc. will post ($3.88) earnings per share for the current year.

In related news, Director John A. Fallon acquired 2,375 shares of the stock in a transaction on Friday, August 12th. The stock was purchased at an average price of $10.59 per share, for a total transaction of $25,151.25. Following the completion of the transaction, the director now owns 2,375 shares of the company’s stock, valued at approximately $25,151.25. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.